Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 86.85 USD 0.65% Market Closed
Market Cap: 50.4B USD

Intrinsic Value

The intrinsic value of one EW stock under the Base Case scenario is 61.35 USD. Compared to the current market price of 86.85 USD, Edwards Lifesciences Corp is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EW Intrinsic Value
61.35 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Edwards Lifesciences Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about EW?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is EW valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Edwards Lifesciences Corp.

Explain Valuation
Compare EW to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Edwards Lifesciences depends heavily on its TAVR franchise, making any slowdown in procedural volumes or tighter site-of-service regulations a significant risk to its top line growth.

Aggressive competition from Medtronic and Boston Scientific in transcatheter valve solutions may compress Edwards’ pricing power and limit future market share gains in key geographies.

Heightened R&D spending and lengthy regulatory timelines for next-generation valve therapies could weigh on margins if newer products fail to gain approval or widespread adoption.

Bull Theses

Edwards Lifesciences holds a leadership position in TAVR technology, particularly with its SAPIEN platform, which remains the gold standard for many heart centers worldwide and drives robust revenue growth.

Their expanding pipeline of transcatheter mitral and tricuspid repair devices positions the company to capitalize on a growing structural heart market beyond aortic valve replacement.

Strong clinical data and consistent investment in physician education support brand loyalty, ensuring Hospitals and cardiologists continue to prefer Edwards’ valves and monitoring systems.

Show More Less
How do you feel about EW?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Edwards Lifesciences Corp

Current Assets 6.4B
Cash & Short-Term Investments 3.8B
Receivables 892.8m
Other Current Assets 1.6B
Non-Current Assets 6.9B
Long-Term Investments 274.7m
PP&E 1.8B
Intangibles 2.9B
Other Non-Current Assets 1.9B
Current Liabilities 1.6B
Accounts Payable 282.6m
Accrued Liabilities 969.4m
Other Current Liabilities 336m
Non-Current Liabilities 1.5B
Long-Term Debt 598.2m
Other Non-Current Liabilities 881m
Efficiency

Free Cash Flow Analysis
Edwards Lifesciences Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Edwards Lifesciences Corp

Revenue
5.9B USD
Cost of Revenue
-1.3B USD
Gross Profit
4.6B USD
Operating Expenses
-3B USD
Operating Income
1.6B USD
Other Expenses
-263.8m USD
Net Income
1.4B USD
Fundamental Scores

EW Profitability Score
Profitability Due Diligence

Edwards Lifesciences Corp's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Positive 3Y Average ROIC
Exceptional Gross Margin
Healthy Operating Margin
60/100
Profitability
Score

Edwards Lifesciences Corp's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

EW Solvency Score
Solvency Due Diligence

Edwards Lifesciences Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Edwards Lifesciences Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EW Price Targets Summary
Edwards Lifesciences Corp

Wall Street analysts forecast EW stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EW is 97.12 USD with a low forecast of 72.72 USD and a high forecast of 110.25 USD.

Lowest
Price Target
72.72 USD
16% Downside
Average
Price Target
97.12 USD
12% Upside
Highest
Price Target
110.25 USD
27% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Edwards Lifesciences Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for EW is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

EW Insider Trading
Buy and sell transactions by insiders

EW News

Other Videos
What is the Intrinsic Value of one EW stock?

The intrinsic value of one EW stock under the Base Case scenario is 61.35 USD.

Is EW stock undervalued or overvalued?

Compared to the current market price of 86.85 USD, Edwards Lifesciences Corp is Overvalued by 29%.

Back to Top